Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs KERNX Health

Two GLP-1 desks, one scoreboard. We put Invigor Medical and KERNX Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 388 · Grade C

KERNX Health

Visit KERNX Health Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 56 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make KERNX Health a bad call — it's best for shoppers who want plan pricing published up front and month-to-month billing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
32
Supply Reliability
88
70
Transparency
84
64
Access Breadth
82
50
Clinical Oversight
88
71
Track Record
90
60
Invigor MedicalBrief Score 88 · 56KERNX Health

Price, coverage & the tracker

Invigor MedicalKERNX Health
Brief Score88/100 (B+)56/100 (C)
Semaglutide$199/moFrom $129/mo (plus a separate fee, compounded)
Tirzepatide$339/moFrom $199/mo (plus a separate fee, compounded)
CoverageNot disclosedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

KERNX Health: New to the tracker on 1 August 2026. The published line reads From $129/mo (plus a separate fee, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.